{"id":35521,"date":"2026-02-10T19:22:56","date_gmt":"2026-02-10T19:22:56","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/cancer-monoclonal-antibodies-market-mordor\/"},"modified":"2026-04-03T14:38:25","modified_gmt":"2026-04-03T05:38:25","slug":"cancer-monoclonal-antibodies-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/cancer-monoclonal-antibodies-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/cancer-monoclonal-antibodies-market_cancer_players.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/cancer-monoclonal-antibodies-market-size-image-1768488681605.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 &amp; \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \uc804 \uc138\uacc4 \uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc885\uc591\ud559 R&amp;D \ud22c\uc790 \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.3 \uc778\uac04\ud654 \ubc0f \uc644\uc804 \uc778\uac04 \ub2e8\uc77c\ud074\ub860\ud56d\uccb4\uc758 \uc785\uc99d\ub41c \uc784\uc0c1 \uc131\uacf5<\/li>\n<li class=\"toc-level-3\">4.2.4 \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4 \ubc0f \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \ucd9c\ud604<\/li>\n<li class=\"toc-level-3\">4.2.5 AI \uae30\ubc18 \ud56d\uccb4 \uacf5\ud559 \ucc44\ud0dd<\/li>\n<li class=\"toc-level-3\">4.2.6 \uac00\uce58 \uae30\ubc18 \uc885\uc591\ud559 \uce58\ub8cc \ubaa8\ub378\ub85c\uc758 \uc804\ud658<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 \uc5c4\uaca9\ud55c \uaddc\uc81c \ubc0f \uc548\uc804 \ubaa8\ub2c8\ud130\ub9c1<\/li>\n<li class=\"toc-level-3\">4.3.2 \ub192\uc740 \uc784\uc0c1 \uc911\ub2e8\uc728 \ubc0f \uae34 \uac1c\ubc1c \uc8fc\uae30<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc0dd\ubb3c\ubc18\uc751\uae30 \ubc0f \uc6d0\ub8cc \uacf5\uae09\uc758 \uc81c\uc870 \ubcd1\ubaa9 \ud604\uc0c1<\/li>\n<li class=\"toc-level-3\">4.3.4 \ucca8\ub2e8 \uce58\ub8cc\ubc95\uacfc\uc758 \uacbd\uc7c1 \uc2ec\ud654<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.5 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778 \ubd84\uc11d\n<ul>\n<li class=\"toc-level-3\">4.5.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.5.2 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.5.3 \uacf5\uae09\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.5.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.5.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (USD \uac00\uce58)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \ud56d\uccb4 \uacf5\uae09\uc6d0\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 \uc950 \uc720\ub798<\/li>\n<li class=\"toc-level-3\">5.1.2 \ud0a4\uba54\ub77c<\/li>\n<li class=\"toc-level-3\">5.1.3 \uc778\uac04\ud654<\/li>\n<li class=\"toc-level-3\">5.1.4 \uc644\uc804 \uc778\uac04<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uce58\ub8cc\ubc95\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \ubca0\ubc14\uc2dc\uc8fc\ub9d9<\/li>\n<li class=\"toc-level-3\">5.2.2 \ud2b8\ub77c\uc2a4\ud22c\uc8fc\ub9d9<\/li>\n<li class=\"toc-level-3\">5.2.3 \ub9ac\ud22d\uc2dc\ub9d9<\/li>\n<li class=\"toc-level-3\">5.2.4 \uc138\ud22d\uc2dc\ub9d9<\/li>\n<li class=\"toc-level-3\">5.2.5 \ub2e4\ub77c\ud22c\ubb34\ub9d9<\/li>\n<li class=\"toc-level-3\">5.2.6 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc554 \uc801\uc6a9 \ubd84\uc57c\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \uc720\ubc29\uc554<\/li>\n<li class=\"toc-level-3\">5.3.2 \ud608\uc561\uc554<\/li>\n<li class=\"toc-level-3\">5.3.3 \ub300\uc7a5\uc554<\/li>\n<li class=\"toc-level-3\">5.3.4 \ud3d0\uc554<\/li>\n<li class=\"toc-level-3\">5.3.5 \uac04 &amp; \uc704\uc7a5\uc554<\/li>\n<li class=\"toc-level-3\">5.3.6 \uae30\ud0c0 \uace0\ud615 \uc885\uc591<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uc720\ud1b5 \ucc44\ub110\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \ubcd1\uc6d0 \uc57d\uad6d<\/li>\n<li class=\"toc-level-3\">5.4.2 \uc18c\ub9e4 \uc57d\uad6d<\/li>\n<li class=\"toc-level-3\">5.4.3 \uc628\ub77c\uc778 \uc57d\uad6d<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.5.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.5.1.3 \uba55\uc2dc\ucf54<\/li>\n<li class=\"toc-level-3\">5.5.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.5.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.5.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.5.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.5.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.5.2.6 \uc720\ub7fd \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<li class=\"toc-level-3\">5.5.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.5.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.5.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.5.3.4 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.5.3.5 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.5.3.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<li class=\"toc-level-3\">5.5.4 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.5.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.5.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.5.4.3 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<li class=\"toc-level-3\">5.5.5 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.5.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.5.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.5.5.3 \ub0a8\ubbf8 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4(\uc0ac\uc6a9 \uac00\ub2a5\ud55c \uacbd\uc6b0), \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 &amp; \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 F. Hoffmann-La Roche Ltd<\/li>\n<li class=\"toc-level-3\">6.3.2 Merck &amp; Co., Inc.<\/li>\n<li class=\"toc-level-3\">6.3.3 Bristol Myers Squibb Co.<\/li>\n<li class=\"toc-level-3\">6.3.4 Amgen Inc.<\/li>\n<li class=\"toc-level-3\">6.3.5 Novartis AG<\/li>\n<li class=\"toc-level-3\">6.3.6 Johnson &amp; Johnson<\/li>\n<li class=\"toc-level-3\">6.3.7 AstraZeneca<\/li>\n<li class=\"toc-level-3\">6.3.8 Eli Lilly and Company<\/li>\n<li class=\"toc-level-3\">6.3.9 Pfizer Inc.<\/li>\n<li class=\"toc-level-3\">6.3.10 GlaxoSmithKline PLC<\/li>\n<li class=\"toc-level-3\">6.3.11 Regeneron Pharmaceuticals<\/li>\n<li class=\"toc-level-3\">6.3.12 AbbVie Inc.<\/li>\n<li class=\"toc-level-3\">6.3.13 Seagen Inc.<\/li>\n<li class=\"toc-level-3\">6.3.14 Daiichi Sankyo Co. Ltd<\/li>\n<li class=\"toc-level-3\">6.3.15 Sanofi SA<\/li>\n<li class=\"toc-level-3\">6.3.16 Genmab A\/S<\/li>\n<li class=\"toc-level-3\">6.3.17 BeiGene Ltd<\/li>\n<li class=\"toc-level-3\">6.3.18 Spectrum Pharmaceuticals Inc.<\/li>\n<li class=\"toc-level-3\">6.3.19 Mitsubishi Tanabe Pharma<\/li>\n<li class=\"toc-level-3\">6.3.20 WuXi Biologics<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c &amp; \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc608\uce21 \ubcf4\uace0\uc11c 2031 \uc694\uc57d<\/p>\n<p>\uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc608\uce21<\/p>\n<p>\uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4(Cancer Monoclonal Antibodies) \uc2dc\uc7a5\uc740 2025\ub144 928.9\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 1,078.2\uc5b5 \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2031\ub144\uc5d0\ub294 2,271.6\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc740 16.07%\ub85c \uc608\uce21\ub429\ub2c8\ub2e4. \ubcf8 \ubcf4\uace0\uc11c\ub294 2020\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0\uc758 \uc2dc\uc7a5\uc744 \ubd84\uc11d\ud558\uba70, \ud56d\uccb4 \uacf5\uae09\uc6d0, \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uce58\ub8cc\ubc95, \uc554 \uc801\uc6a9 \ubd84\uc57c, \uc720\ud1b5 \ucc44\ub110 \ubc0f \uc9c0\uc5ed\ubcc4\ub85c \uc2dc\uc7a5\uc744 \uc138\ubd84\ud654\ud558\uc5ec \uac00\uce58(USD) \uae30\uc900\uc73c\ub85c \uc608\uce21\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc774 \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc740 \uc778\uacf5\uc9c0\ub2a5(AI) \uae30\ubc18 \ud56d\uccb4 \uc124\uacc4, \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4(bispecific antibodies)\uc758 \uc2e0\uc18d\ud55c \uaddc\uc81c \uc2b9\uc778 \uacbd\ub85c, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\uc758 \uad11\ubc94\uc704\ud55c \ucc44\ud0dd\uc5d0 \ud798\uc785\uc5b4 \uce58\ub8cc \ubc94\uc704\uac00 \ud655\ub300\ub418\uace0 \uc218\uc775 \uac00\uc2dc\uc131\uc774 \ub192\uc544\uc9c0\ub294 \ub370 \uae30\uc778\ud569\ub2c8\ub2e4. \uacc4\uc57d \uc81c\uc870\uc5c5\uccb4\uc758 \uc0dd\uc0b0 \ub2a5\ub825 \ud655\uc7a5, \uac00\uce58 \uae30\ubc18 \uc885\uc591\ud559 \uce58\ub8cc\ub85c\uc758 \uc804\ud658, \uc911\uad6d \ubc14\uc774\uc624\uae30\uc220 \uae30\uc5c5\uc758 \ud68d\uae30\uc801\uc778 \uc784\uc0c1 \ub370\uc774\ud130 \ub610\ud55c \uacbd\uc7c1 \uc5ed\ud559\uc744 \uc7ac\ud3b8\ud558\uba70 \ud30c\uc774\ud504\ub77c\uc778 \uc0dd\uc0b0\uc131\uc744 \ub192\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \ud1b5\uacc4 (2025\ub144 \uae30\uc900)<\/p>\n<p>*   \uc2dc\uc7a5 \uaddc\ubaa8 (2026\ub144): 1,078.2\uc5b5 \ub2ec\ub7ec<br \/>\n*   \uc2dc\uc7a5 \uaddc\ubaa8 (2031\ub144): 2,271.6\uc5b5 \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026-2031): 16.07% CAGR<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04<\/p>\n<p>\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>*   \ud56d\uccb4 \uacf5\uae09\uc6d0\ubcc4: 2025\ub144 \ud734\uba3c\ud654 \ud56d\uccb4\uac00 \uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 50.62%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc644\uc804 \uc778\uac04 \ud56d\uccb4\ub294 2031\ub144\uae4c\uc9c0 18.59%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uce58\ub8cc\ubc95\ubcc4: 2025\ub144 \ud2b8\ub77c\uc2a4\ud22c\uc8fc\ub9d9(Trastuzumab)\uc774 \uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 16.72%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, &#8216;\uae30\ud0c0&#8217; \ubc94\uc8fc\ub294 2026-2031\ub144 \ub3d9\uc548 20.61%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc554 \uc801\uc6a9 \ubd84\uc57c\ubcc4: 2025\ub144 \uc720\ubc29\uc554\uc774 \uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 25.12%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uac04\uc554 \ubc0f \uc704\uc7a5\uad00\uc554\uc740 2031\ub144\uae4c\uc9c0 16.41%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<br \/>\n*   \uc720\ud1b5 \ucc44\ub110\ubcc4: 2025\ub144 \ubcd1\uc6d0 \uc57d\uad6d\uc774 \ub9e4\ucd9c\uc758 52.24%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc628\ub77c\uc778 \uc57d\uad6d\uc740 2031\ub144\uae4c\uc9c0 17.95%\uc758 CAGR\ub85c \uac00\uc7a5 \ub192\uc740 \uc131\uc7a5\ub960\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \ubcf4\uc785\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\uac00 \uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 41.78%\ub97c \uc720\uc9c0\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc740 2031\ub144\uae4c\uc9c0 18.92%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \ud655\uc7a5\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5 \ub3d9\uc778<\/p>\n<p>\uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \uc694\uc778\ub4e4\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>*   \uc804 \uc138\uacc4 \uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00: 2022\ub144 2\ucc9c\ub9cc \uac74\uc5d0\uc11c 2050\ub144 3\ucc9c5\ubc31\ub9cc \uac74\uc73c\ub85c 77% \uc99d\uac00\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\ub294 \uc554 \ubc1c\ubcd1\ub960\uc740 \ud3d0\uc554, \uc720\ubc29\uc554, \ub300\uc7a5\uc554 \ub4f1 \ub2e4\uc591\ud55c \uc554\uc885\uc5d0\uc11c \ud658\uc790 \ud480\uc744 \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uace0\ub839\ud654 \uc0ac\ud68c\uc640 \uc2e0\ud765 \uacbd\uc81c\uad6d\uc758 \uc0dd\ud65c \uc2b5\uad00 \ubcc0\ud654\ub294 \ud45c\uc801 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\uc5d0 \ub300\ud55c \uc218\uc694\ub97c \uc99d\ud3ed\uc2dc\ud0a4\uba70, \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4\uac00 \uc815\ubc00 \uc885\uc591\ud559 \ud504\ub85c\ud1a0\ucf5c\uc5d0 \ubd80\ud569\ud558\ub294 \uc885\uc591 \ud2b9\uc774\uc801 \uc791\uc6a9\uc744 \uc81c\uacf5\ud568\uc5d0 \ub530\ub77c \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \uae30\uc5ec\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +3.2%, \uc7a5\uae30\uc801, \uc804 \uc138\uacc4\uc801)<br \/>\n*   \uc885\uc591\ud559 R&#038;D \ud22c\uc790 \ud655\ub300: \uc885\uc591\ud559\uc740 \uc0dd\ubb3c\uc81c\uc57d R&#038;D \uc608\uc0b0\uc5d0\uc11c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud558\uba70, \uc885\uc591\ud559 \uc784\uc0c1 \uc2dc\ud5d8\uc758 35%\uac00 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4 \ub610\ub294 \ub2e4\uc911\ud2b9\uc774\uc131 \uad6c\uc870\ub97c \ud3ec\ud568\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uac1c\ubc1c \uc0dd\uc0b0\uc131 \ud5a5\uc0c1\uacfc \ube14\ub85d\ubc84\uc2a4\ud130\uae09 \uc778\uc218\ud569\ubcd1(\uc608: Bristol Myers Squibb\uc758 Mirati \uc778\uc218, Eli Lilly\uc758 Point Biopharma \uc778\uc218)\uc740 \ud6c4\uae30 \ub2e8\uacc4 \ud30c\uc774\ud504\ub77c\uc778\uc744 \uac15\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +2.8%, \uc911\uae30\uc801, \ubd81\ubbf8 \ubc0f EU)<br \/>\n*   \ud734\uba3c\ud654 \ubc0f \uc644\uc804 \uc778\uac04 \ud56d\uccb4\uc758 \uc784\uc0c1\uc801 \uc131\uacf5 \uc785\uc99d: 2024\ub144 \uaddc\uc81c \ub2f9\uad6d\uc740 25\uac1c\uc758 \uc0c8\ub85c\uc6b4 \uc885\uc591\ud559 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\ub97c \uc2b9\uc778\ud588\uc73c\uba70, \uc774\ub4e4 \uc911 \ub2e4\uc218\ub294 \uba74\uc5ed\uc6d0\uc131\uc744 \ub0ae\ucd98 \ud734\uba3c\ud654 \ub610\ub294 \uc644\uc804 \uc778\uac04 \ud56d\uccb4 \ud615\ud0dc\ub97c \uae30\ubc18\uc73c\ub85c \ud569\ub2c8\ub2e4. \ud53c\ud558 \ud22c\uc5ec \uc81c\ud615\uc740 \ud22c\uc5ec \uc2dc\uac04\uc744 \ub2e8\ucd95\ud558\uc5ec \ud658\uc790 \uc21c\uc751\ub3c4\ub97c \ub192\uc774\uace0 \uc8fc\uc785 \uc6a9\ub7c9\uc744 \ud655\ubcf4\ud569\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +2.1%, \ub2e8\uae30\uc801, \uc804 \uc138\uacc4\uc801)<br \/>\n*   \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4 \ubc0f \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\uc758 \ub4f1\uc7a5: 2023\ub144 \ub9d0\uae4c\uc9c0 14\uac1c\uc758 \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4\uac00 \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uc2b9\uc778\ub418\uc5c8\uc73c\uba70, \uc2dc\ud310 \uc911\uc778 ADCs\uc640 \ud568\uaed8 2028\ub144\uae4c\uc9c0 260\uc5b5 \ub2ec\ub7ec \uc774\uc0c1\uc758 \ub9e4\ucd9c\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \ubcf5\uc7a1\ud55c \uc81c\uc870 \uacf5\uc815\uc740 \uc9c4\uc785 \uc7a5\ubcbd\uc744 \ub192\uc5ec \ud601\uc2e0 \uae30\uc5c5\uc744 \ubcf4\ud638\ud558\ub294 \ub3d9\uc2dc\uc5d0 \uacc4\uc57d \uc81c\uc870 \uc218\uc694\ub97c \ucd09\uc9c4\ud569\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +4.3%, \uc911\uae30\uc801, \uc804 \uc138\uacc4\uc801, \uc911\uad6d\uc774 \uc784\uc0c1 \uc8fc\ub3c4)<br \/>\n*   AI \uae30\ubc18 \ud56d\uccb4 \uacf5\ud559 \ucc44\ud0dd: AI \uae30\ubc18 \ud56d\uccb4 \uacf5\ud559\uc758 \ub3c4\uc785\uc740 \ud56d\uccb4 \uc124\uacc4 \ubc0f \uac1c\ubc1c \uacfc\uc815\uc744 \uac00\uc18d\ud654\ud558\uc5ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc758 \ud6a8\uc728\uc131\uc744 \ub192\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +1.9%, \uc7a5\uae30\uc801, \ubd81\ubbf8 \ubc0f EU, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \ud655\uc7a5 \uc911)<br \/>\n*   \uac00\uce58 \uae30\ubc18 \uc885\uc591\ud559 \ubaa8\ub378\ub85c\uc758 \uc804\ud658: \uac00\uce58 \uae30\ubc18 \uc758\ub8cc \ubaa8\ub378\ub85c\uc758 \uc804\ud658\uc740 \ube44\uc6a9 \ud6a8\uc728\uc801\uc774\uace0 \ud6a8\uacfc\uc801\uc778 \uce58\ub8cc\ubc95\uc5d0 \ub300\ud55c \uc218\uc694\ub97c \uc99d\uac00\uc2dc\ud0a4\uba70, \uc774\ub294 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5\uc5d0 \uae0d\uc815\uc801\uc778 \uc601\ud5a5\uc744 \ubbf8\uce69\ub2c8\ub2e4. (CAGR \uc601\ud5a5 +1.3%, \uc911\uae30\uc801, \ubd81\ubbf8 \ubc0f EU)<\/p>\n<p>\uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778<\/p>\n<p>\uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc8fc\uc694 \uc694\uc778\ub4e4\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>*   \uc5c4\uaca9\ud55c \uaddc\uc81c \ubc0f \uc548\uc804\uc131 \ubaa8\ub2c8\ud130\ub9c1: \uaddc\uc81c \uae30\uad00\uc740 \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4 \ubc0f ADCs\uc5d0 \ub300\ud55c \ud1b5\ud569 \uc548\uc804\uc131 \ub370\uc774\ud130\ub97c \uc694\uad6c\ud558\uba70, \uc18c\uc544 \uc5f0\uad6c \uaddc\uc815 \ubc0f \ube44\uad50 \ud6a8\uacfc \uac80\ud1a0\ub97c \ucd94\uac00\ud558\uc5ec \uac1c\ubc1c \uae30\uac04\uacfc \ube44\uc6a9\uc744 \uc99d\uac00\uc2dc\ud0b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 -2.1%, \ub2e8\uae30\uc801, \uc804 \uc138\uacc4\uc801, \uc120\uc9c4 \uc2dc\uc7a5\uc5d0\uc11c \uac00\uc7a5 \uac15\ud568)<br \/>\n*   \ub192\uc740 \uc784\uc0c1 \uc2e4\ud328\uc728 \ubc0f \uae34 \uac1c\ubc1c \uc8fc\uae30: \uc2e0\uc57d \uac1c\ubc1c\uc758 \ubcf8\uc9c8\uc801\uc778 \ud2b9\uc131\uc0c1 \ub192\uc740 \uc784\uc0c1 \uc2e4\ud328\uc728\uacfc \uae34 \uac1c\ubc1c \uc8fc\uae30\ub294 \ud2b9\ud788 \uc18c\uaddc\ubaa8 \uae30\uc5c5\uc5d0 \ud070 \ubd80\ub2f4\uc73c\ub85c \uc791\uc6a9\ud569\ub2c8\ub2e4. (CAGR \uc601\ud5a5 -1.8%, \uc7a5\uae30\uc801, \uc804 \uc138\uacc4\uc801)<br \/>\n*   \uc0dd\ubb3c\ubc18\uc751\uae30 \ubc0f \uc6d0\uc790\uc7ac \uacf5\uae09\uc758 \ubcd1\ubaa9 \ud604\uc0c1: 2024\ub144 \uc804 \uc138\uacc4 \uc0dd\ubb3c\ubc18\uc751\uae30 \uc6a9\ub7c9\uc740 1,740\ub9cc \ub9ac\ud130\uc5d0 \ub2ec\ud588\uc9c0\ub9cc, \uc218\uc694 \uc99d\uac00\uac00 \uc5ec\uc804\ud788 \uacf5\uae09 \ub2a5\ub825\uc744 \ucd08\uacfc\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc138\ud3ec \ubc30\uc591 \ubc30\uc9c0 \ubc0f \uc77c\ud68c\uc6a9 \ubc31\uc758 \ubd80\uc871\uc740 \ub9ac\ub4dc \ud0c0\uc784 \uc778\ud50c\ub808\uc774\uc158\uc744 \uc720\ubc1c\ud558\uba70, \uc774\ub294 \uacc4\uc57d \uc81c\uc870 \ube44\uc6a9\uc744 \uc0c1\uc2b9\uc2dc\ud0a4\uace0 \uc81c\ud488 \ucd9c\uc2dc\ub97c \uc9c0\uc5f0\uc2dc\ud0ac \uc218 \uc788\uc2b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 -2.3%, \uc911\uae30\uc801, \uc804 \uc138\uacc4\uc801, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uad6c\ucd95\uc5d0 \uc2ec\uac01)<br \/>\n*   \ucca8\ub2e8 \uce58\ub8cc\ubc95\uacfc\uc758 \uacbd\uc7c1 \uc2ec\ud654: CAR-T \ubc0f \uc720\uc804\uc790 \ud3b8\uc9d1 \uce58\ub8cc\ubc95\uacfc \uac19\uc740 \ucca8\ub2e8 \uce58\ub8cc\ubc95\uc758 \ub4f1\uc7a5\uc740 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5\uc5d0 \uacbd\uc7c1 \uc555\ub825\uc744 \uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. (CAGR \uc601\ud5a5 -1.4%, \uc7a5\uae30\uc801, \ubd81\ubbf8 \ubc0f EU, \uc804 \uc138\uacc4\ub85c \ud655\ub300)<\/p>\n<p>\uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>*   \ud56d\uccb4 \uacf5\uae09\uc6d0\ubcc4: \ud734\uba3c\ud654 \ud56d\uccb4\ub294 2025\ub144 \ub9e4\ucd9c\uc758 50.62%\ub97c \ucc28\uc9c0\ud558\uba70 \uc2dc\uc7a5\uc744 \uc8fc\ub3c4\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc644\uc804 \uc778\uac04 \ud56d\uccb4\ub294 \uc6b0\uc218\ud55c \uc548\uc804\uc131\uacfc \ubcd1\uc6a9 \uc694\ubc95\uc5d0\uc11c\uc758 \uc0ac\uc6a9 \uc99d\uac00\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 18.59%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc81c\uc870 \uacf5\uc815\uc758 \ub2e8\uc21c\uc131\uacfc \uc720\ub9ac\ud55c \uaddc\uc81c \ud504\ub85c\ud30c\uc77c\uc740 \uc644\uc804 \uc778\uac04 \ud56d\uccb4\uac00 \uc608\uce21 \uae30\uac04 \ub3d9\uc548 \ud2c8\uc0c8\uc2dc\uc7a5\uc5d0\uc11c \uc8fc\ub958\ub85c \uc774\ub3d9\ud560 \uc218 \uc788\ub294 \uae30\ubc18\uc744 \ub9c8\ub828\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uce58\ub8cc\ubc95\ubcc4: \ud2b8\ub77c\uc2a4\ud22c\uc8fc\ub9d9\uc740 HER2 \uc591\uc131 \uc720\ubc29\uc554 \ubd84\uc57c\uc5d0\uc11c\uc758 \uae4a\uc740 \uc758\uc0ac \uce5c\uc219\ub3c4\uc640 \uac15\ub825\ud55c \uc99d\uac70\ub97c \ubc14\ud0d5\uc73c\ub85c 2025\ub144 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 16.72%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 ADCs \ubc0f \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4\ub97c \uc911\uc2ec\uc73c\ub85c \ud55c \ud601\uc2e0 \ubb3c\uacb0\uc740 &#8216;\uae30\ud0c0&#8217; \ubc94\uc8fc\ub97c \uc5f0\uac04 20.61% \uc131\uc7a5\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc0c8\ub85c\uc6b4 \uc2b9\uc778(\uc608: HER2-low \uc9c8\ud658\uc6a9 \ud2b8\ub77c\uc2a4\ud22c\uc8fc\ub9d9 \ub370\ub8e9\uc2a4\ud14c\uce78)\uc740 \ub354 \ub113\uc740 \ud658\uc790\uad70\uc5d0\uac8c \ud61c\ud0dd\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<br \/>\n*   \uc554 \uc801\uc6a9 \ubd84\uc57c\ubcc4: \uc720\ubc29\uc554\uc740 HER2 \ud45c\uc801 \uc694\ubc95\uc758 \ud655\uace0\ud55c \uc785\uc9c0\uc640 \ud638\ub974\ubaac \uc218\uc6a9\uccb4 \uc591\uc131 \ud658\uacbd\uc5d0\uc11c\uc758 \ucc44\ud0dd \uc99d\uac00\ub85c 2025\ub144 \uc2dc\uc7a5 \uaddc\ubaa8\uc758 25.12%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uac04\uc554 \ubc0f \uc704\uc7a5\uad00\uc554\uc740 TROP2 \ubc0f EGFR \ubcc0\uc774\uc640 \uac19\uc740 \uc2e0\ud765 \ud45c\uc801\uc774 \ud6c4\uae30 \ub2e8\uacc4 \uc784\uc0c1 \uc2dc\ud5d8\uc73c\ub85c \uc9c4\uc785\ud568\uc5d0 \ub530\ub77c 2031\ub144\uae4c\uc9c0 16.41%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc720\ud1b5 \ucc44\ub110\ubcc4: \ubcd1\uc6d0 \uc57d\uad6d\uc740 \ub9ce\uc740 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4\uac00 \uc5ec\uc804\ud788 \uac10\ub3c5 \ud558\uc5d0 \uc8fc\uc785\ub418\uc5b4\uc57c \ud558\ubbc0\ub85c 2025\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 52.24%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \ud53c\ud558 \uc8fc\uc0ac \uc81c\ud615\uc740 \ud658\uc790\ub4e4\uc774 \uc790\uac00 \ud22c\uc5ec\ub97c \uc218\uc6a9\ud568\uc5d0 \ub530\ub77c \uc628\ub77c\uc778 \uc57d\uad6d \ub9e4\ucd9c\uc744 17.95%\uc758 CAGR\ub85c \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc9c0\uc5ed \ubd84\uc11d<\/p>\n<p>*   \ubd81\ubbf8: 2025\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 41.78%\ub97c \ucc28\uc9c0\ud558\uba70 \uc120\ub450\ub97c \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uac15\ub825\ud55c \uc784\uc0c1 \uc2dc\ud5d8 \uc0dd\ud0dc\uacc4\uc640 \uc6b0\ud638\uc801\uc778 \ubcf4\ud5d8 \uc815\ucc45\uc5d0 \ud798\uc785\uc740 \uacb0\uacfc\uc785\ub2c8\ub2e4. \ud53c\ud558 \uc8fc\uc0ac \ud3a8\ube0c\ub864\ub9ac\uc8fc\ub9d9(pembrolizumab) \uc2b9\uc778\uc740 \ud658\uc790 \uc911\uc2ec \ud22c\uc5ec\ub97c \uc704\ud55c \uc9c0\uc5ed\uc758 \ub178\ub825\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: 2031\ub144\uae4c\uc9c0 18.92%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ub294 \uc885\uc591\ud559 \uc608\uc0b0 \uc99d\uac00, \uc778\uad6c \uace0\ub839\ud654, \uaddc\uc81c \uae30\uad00\uc758 \uc2e0\uc18d \uc2b9\uc778 \uacbd\ub85c \uc9c0\uc6d0\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \uc911\uad6d\uc758 Akeso\uac00 Keytruda\ubcf4\ub2e4 \uc6b0\uc218\ud55c \uacb0\uacfc\ub97c \ubcf4\uc778 \uc774\ubcf4\ub124\uc2dc\ub9d9(ivonescimab)\uc744 \uac1c\ubc1c\ud558\ub294 \ub4f1 \uad6d\ub0b4 \ud56d\uccb4 \ud50c\ub7ab\ud3fc\uc5d0 \ub300\ud55c \uc2e0\ub8b0\uc640 \ud22c\uc790\ub97c \uc720\uce58\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: \uc2b9\uc778 \uc808\ucc28\ub97c \uac04\uc18c\ud654\ud558\uba74\uc11c\ub3c4 \uc608\uc0b0\uc744 \uad00\ub9ac\ud558\ub294 \uacf5\ub3d9 \uc784\uc0c1 \ud3c9\uac00\ub97c \ud1b5\ud574 \uade0\ud615 \uc7a1\ud78c \uc811\uadfc \ubc29\uc2dd\uc744 \ucd94\uad6c\ud569\ub2c8\ub2e4. \ub9b0\ubcf4\uc140\ud0c0\ub9d9(linvoseltamab)\uacfc \uac19\uc740 \ud68d\uae30\uc801\uc778 \ud56d\uccb4\uc5d0 \ub300\ud55c \uc870\uac74\ubd80 \ud310\ub9e4 \ud5c8\uac00\ub294 \ub192\uc740 \ubbf8\ucda9\uc871 \uc218\uc694\ub97c \ud574\uacb0\ud558\ub294 \ub370 \uc788\uc5b4 \ubbfc\ucca9\uc131\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<br \/>\n*   \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8: \uc815\ubd80\uac00 \ubcf4\ud3b8\uc801 \uc758\ub8cc \ubcf4\uc7a5 \uacc4\ud68d\uc5d0\uc11c \uc885\uc591\ud559\uc744 \uc6b0\uc120\uc21c\uc704\uc5d0 \ub450\uba74\uc11c \uc810\uc9c4\uc801\uc778 \uc131\uc7a5\uc744 \ubcf4\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc678\uad6d\uc778 \uc9c1\uc811 \ud22c\uc790\ub294 \uc218\uc785 \uc8fc\uae30\ub97c \ub2e8\ucd95\ud558\ub294 \uc644\uc81c \uc758\uc57d\ud488 \uc0dd\uc0b0 \uacf5\uc7a5\uc73c\ub85c \uc720\uc785\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubc0f \uc8fc\uc694 \uae30\uc5c5<\/p>\n<p>\uc554 \ub2e8\uc77c\ud074\ub860 \ud56d\uccb4 \uc2dc\uc7a5\uc740 \uc911\uac04 \uc815\ub3c4\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4. \uc11c\uad6c\uc758 \uc8fc\uc694 \uae30\uc5c5\ub4e4\uc774 \uc5ec\uc804\ud788 \ud070 \ud3ec\ud2b8\ud3f4\ub9ac\uc624\ub97c \ubcf4\uc720\ud558\uace0 \uc788\uc9c0\ub9cc, \uc544\uc2dc\uc544 \ubc14\uc774\uc624\uae30\uc220 \uae30\uc5c5\ub4e4\uc740 \uacbd\uc7c1\ub825 \uc788\ub294 \uc784\uc0c1 \ub370\uc774\ud130\uc640 \ub0ae\uc740 \uac1c\ubc1c \ube44\uc6a9\uc73c\ub85c \uc2dc\uc7a5\uc744 \uad50\ub780\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uacc4\uc57d \uc81c\uc870\uc758 \ud655\uc0b0\uacfc \ub192\uc740 \uc2e0\uc57d \ubc1c\uacac \ubcf5\uc7a1\uc131\uc740 \uc9c4\uc785 \uc7a5\ubcbd\uc744 \ud615\uc131\ud558\uc5ec \uc2dc\uc7a5 \ubd84\uc5f4 \uc555\ub825\uc744 \ubd80\ubd84\uc801\uc73c\ub85c \uc0c1\uc1c4\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc804\ub7b5\uc801 M&#038;A \ubc0f \ub77c\uc774\uc120\uc2f1 \uacc4\uc57d\uc774 \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc608\ub97c \ub4e4\uc5b4, Pfizer\ub294 3SBio\uc640 PD-1\/VEGF \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4\uc5d0 \ub300\ud55c 12.5\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\uc758 \uae00\ub85c\ubc8c \uacc4\uc57d\uc744 \uccb4\uacb0\ud588\uc73c\uba70, BioNTech\uc640 Bristol Myers Squibb\ub294 BNT327 \uacf5\ub3d9 \uac1c\ubc1c\uc744 \uc704\ud574 15\uc5b5 \ub2ec\ub7ec\ub97c \uc120\uc9c0\uae09\ud588\uc2b5\ub2c8\ub2e4. \uc8fc\uc694 \uae30\uc5c5\ub4e4\uc740 AI \ub3c4\uad6c\ub97c \ud1b5\ud569\ud558\uace0, \uc5f0\uc18d \uc0dd\ubb3c\uacf5\uc815\uc5d0 \ud22c\uc790\ud558\uba70, \ud658\uc790 \uc9c0\uc6d0 \uc0dd\ud0dc\uacc4\ub97c \uad6c\ucd95\ud558\uc5ec \uc21c\uc751\ub3c4\ub97c \uac1c\uc120\ud558\uace0 \uc11c\ube44\uc2a4 \ud488\uc9c8\uc744 \ucc28\ubcc4\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \ucc38\uc5ec \uae30\uc5c5\uc73c\ub85c\ub294 Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd (Genentech Inc), Merck &#038; Co., Inc., Novartis AG \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2025\ub144 6\uc6d4: BioNTech\uc640 Bristol Myers Squibb\ub294 PD-L1 \ubc0f VEGF-A\ub97c \ud45c\uc801\ud558\ub294 \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4 BNT327\uc758 \uacf5\ub3d9 \uac1c\ubc1c\uc744 \uc704\ud55c \uae00\ub85c\ubc8c \uc804\ub7b5\uc801 \ud30c\ud2b8\ub108\uc2ed\uc744 \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4. \uc120\uc9c0\uae09\uae08 15\uc5b5 \ub2ec\ub7ec\uc640 \uc7a0\uc7ac\uc801 \ub9c8\uc77c\uc2a4\ud1a4 \uc9c0\uae09\uc561 \ucd1d 76\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\uc785\ub2c8\ub2e4.<br \/>\n*   2025\ub144 6\uc6d4: Roche\ub294 Tecentriq\uc640 lurbinectedin \ubcd1\uc6a9 \uc694\ubc95\uc774 \uad11\ubc94\uc704 \uc18c\uc138\ud3ec \ud3d0\uc554 \ud658\uc790\uc758 \uc0dd\uc874\uc728\uc744 \uc720\uc758\ubbf8\ud558\uac8c \uac1c\uc120\ud588\uc74c\uc744 \ubcf4\uc5ec\uc8fc\ub294 \uae0d\uc815\uc801\uc778 \uc784\uc0c1 3\uc0c1 IMforte \uc5f0\uad6c \uacb0\uacfc\ub97c \ubcf4\uace0\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 5\uc6d4: Pfizer\ub294 3SBio\uc640 PD-1 \ubc0f VEGF\ub97c \ud45c\uc801\ud558\ub294 \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4 SSGJ-707\uc5d0 \ub300\ud55c \ub3c5\uc810 \uae00\ub85c\ubc8c \ub77c\uc774\uc120\uc2f1 \uacc4\uc57d\uc744 \uccb4\uacb0\ud588\uc2b5\ub2c8\ub2e4. \uc120\uc9c0\uae09\uae08 12.5\uc5b5 \ub2ec\ub7ec\uc640 \uc7a0\uc7ac\uc801 \ub9c8\uc77c\uc2a4\ud1a4 \uc9c0\uae09\uc561 \ucd5c\ub300 48\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\uc785\ub2c8\ub2e4.<br \/>\n*   2025\ub144 4\uc6d4: FDA\ub294 \ube44\uac01\uc9c8\ud654 \ube44\uc778\ub450\uc554 \uce58\ub8cc\uc81c penpulimab-kcqx\ub97c \uc2b9\uc778\ud588\uc2b5\ub2c8\ub2e4. \uc774 \ubcd1\uc6a9 \uc694\ubc95\uc740 9.6\uac1c\uc6d4\uc758 \uc911\uc559 \ubb34\uc9c4\ud589 \uc0dd\uc874 \uae30\uac04\uc744 \ubcf4\uc600\uc73c\uba70, \uc2e0\uc18d \uc2ec\uc0ac, \ud601\uc2e0 \uce58\ub8cc\uc81c, \ud76c\uadc0 \uc758\uc57d\ud488 \uc9c0\uc815\uc744 \ubc1b\uc558\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc554 \ub2e8\uc77c\ud074\ub860\ud56d\uccb4(mAbs) \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \uc774 \uc2dc\uc7a5\uc740 \uace0\ud615\uc554 \ub610\ub294 \ud608\uc561\uc554\uc758 \uc9c4\ub2e8 \ubc0f \uce58\ub8cc\ub97c \uc704\ud574 \uaddc\uc81c \uae30\uad00\uc758 \uc2b9\uc778\uc744 \ubc1b\uc740 \ubaa8\ub4e0 \ucc98\ubc29 \ub4f1\uae09 \ud56d\uccb4 \ubd84\uc790\ub97c \ud3ec\ud568\ud558\uba70, \uacf5\uc7a5 \ucd9c\ud558 \uac00\uaca9 \uae30\uc900\uc73c\ub85c \ubcd1\uc6d0, \uc18c\ub9e4 \ubc0f \uc628\ub77c\uc778 \uc57d\uad6d \ucc44\ub110\uc744 \ud1b5\ud55c \ub9e4\ucd9c\uc744 \ud3c9\uac00\ud569\ub2c8\ub2e4. \ube48\ud608, \ud638\uc911\uad6c \uac10\uc18c\uc99d \ub610\ub294 \uc790\uac00\uba74\uc5ed \uc9c8\ud658\uc5d0\ub9cc \uc0ac\uc6a9\ub418\ub294 \ubcf4\uc870 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\ub294 \ubd84\uc11d \ubc94\uc704\uc5d0\uc11c \uc81c\uc678\ub429\ub2c8\ub2e4.<\/p>\n<p>\ubcf4\uace0\uc11c\uc5d0 \ub530\ub974\uba74, \uc554 \ub2e8\uc77c\ud074\ub860\ud56d\uccb4 \uc2dc\uc7a5\uc740 2026\ub144 1,078\uc5b5 2\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc5d0\uc11c 2031\ub144\uae4c\uc9c0 2,271\uc5b5 6\ucc9c\ub9cc \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc740 16.07%\uc5d0 \ub2ec\ud569\ub2c8\ub2e4. \ud2b9\ud788 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uc911\uad6d\uc758 \ub300\uaddc\ubaa8 \uc784\uc0c1\uc2dc\ud5d8 \ud30c\uc774\ud504\ub77c\uc778\uacfc \uc81c\uc870 \uc5ed\ub7c9 \ud655\uc7a5\uc5d0 \ud798\uc785\uc5b4 18.92%\uc758 \uac00\uc7a5 \ub192\uc740 CAGR\uc744 \uae30\ub85d\ud558\uba70 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5\uc758 \uc8fc\uc694 \ub3d9\ub825\uc73c\ub85c\ub294 \uc804 \uc138\uacc4\uc801\uc778 \uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00, \ud56d\uc554 R&#038;D \ud22c\uc790 \ud655\ub300, \uc778\uac04\ud654 \ubc0f \uc644\uc804 \uc778\uac04 \ud56d\uccb4\uc758 \uc784\uc0c1\uc801 \uc131\uacf5 \uc785\uc99d, \uc774\uc911\ud2b9\uc774\uc131 \ud56d\uccb4(Bispecific Antibodies) \ubc0f \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\uc758 \ub4f1\uc7a5, AI \uae30\ubc18 \ud56d\uccb4 \uacf5\ud559 \uae30\uc220 \ub3c4\uc785, \uadf8\ub9ac\uace0 \uac00\uce58 \uae30\ubc18 \ud56d\uc554 \uce58\ub8cc \ubaa8\ub378\ub85c\uc758 \uc804\ud658 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4. \ubc18\uba74, \uc5c4\uaca9\ud55c \uaddc\uc81c \ubc0f \uc548\uc804\uc131 \ubaa8\ub2c8\ud130\ub9c1, \ub192\uc740 \uc784\uc0c1 \uc2e4\ud328\uc728\uacfc \uae34 \uac1c\ubc1c \uc8fc\uae30, \uc0dd\ubb3c\ubc18\uc751\uae30 \ubc0f \uc6d0\uc790\uc7ac \uacf5\uae09\uc758 \ubcd1\ubaa9 \ud604\uc0c1, CAR-T \ubc0f \uc720\uc804\uc790 \ud3b8\uc9d1 \uce58\ub8cc\uc81c\uc640 \uac19\uc740 \ucca8\ub2e8 \uce58\ub8cc\ubc95\uacfc\uc758 \uacbd\uc7c1 \uc2ec\ud654\ub294 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c \uc791\uc6a9\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5\uc740 \ub2e4\uc591\ud55c \uae30\uc900\uc73c\ub85c \uc138\ubd84\ud654\ub418\uc5b4 \ubd84\uc11d\ub429\ub2c8\ub2e4.<br \/>\n*   \ud56d\uccb4 \uacf5\uae09\uc6d0\ubcc4: \ub9c8\uc6b0\uc2a4 \uc720\ub798(Murine), \ud0a4\uba54\ub77c(Chimeric), \uc778\uac04\ud654(Humanized), \uc644\uc804 \uc778\uac04(Fully-Human) \ud56d\uccb4\ub85c \ub098\ub258\uba70, \uc778\uac04\ud654 \ud56d\uccb4\uac00 50.62%\uc758 \ub9e4\ucd9c \uc810\uc720\uc728\ub85c \uc120\ub450\ub97c \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uba74\uc5ed\uc6d0\uc131\uc774 \ub0ae\uace0 \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ud3ed\ub113\uac8c \ud65c\uc6a9\ub420 \uc218 \uc788\ub294 \uc644\uc804 \uc778\uac04 \ud56d\uccb4\uac00 18.59%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub2e8\uc77c\ud074\ub860\ud56d\uccb4 \uce58\ub8cc\uc81c\ubcc4: \ubca0\ubc14\uc2dc\uc8fc\ub9d9(Bevacizumab), \ud2b8\ub77c\uc2a4\ud22c\uc8fc\ub9d9(Trastuzumab), \ub9ac\ud22d\uc2dc\ub9d9(Rituximab), \uc138\ud22d\uc2dc\ub9d9(Cetuximab), \ub2e4\ub77c\ud22c\ubb34\ub9d9(Daratumumab) \ub4f1 \uc8fc\uc694 \uce58\ub8cc\uc81c\uc640 \uae30\ud0c0 \uc81c\ud488\uad70\uc744 \ub2e4\ub8f9\ub2c8\ub2e4.<br \/>\n*   \uc554 \uc801\uc6a9 \ubd84\uc57c\ubcc4: \uc720\ubc29\uc554, \ud608\uc561\uc554, \ub300\uc7a5\uc554, \ud3d0\uc554, \uac04 \ubc0f \uc704\uc7a5\uad00\uc554, \uae30\ud0c0 \uace0\ud615\uc554 \ub4f1 \ub2e4\uc591\ud55c \uc554\uc885\uc5d0 \ub300\ud55c \uc801\uc6a9\uc744 \ubd84\uc11d\ud569\ub2c8\ub2e4.<br \/>\n*   \uc720\ud1b5 \ucc44\ub110\ubcc4: \ubcd1\uc6d0 \uc57d\uad6d\uc774 52.24%\uc758 \uc810\uc720\uc728\ub85c \uc5ec\uc804\ud788 \uc9c0\ubc30\uc801\uc774\uc9c0\ub9cc, \ud53c\ud558 \uc8fc\uc0ac \uc81c\ud615\uc758 \ub4f1\uc7a5\uc73c\ub85c \uc790\uac00 \ud22c\uc5ec\uac00 \uac00\ub2a5\ud574\uc9c0\uba74\uc11c \uc628\ub77c\uc778 \uc57d\uad6d\uc774 17.95%\uc758 CAGR\ub85c \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc18c\ub9e4 \uc57d\uad6d\ub3c4 \ud3ec\ud568\ub429\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: \ubd81\ubbf8(\ubbf8\uad6d, \uce90\ub098\ub2e4, \uba55\uc2dc\ucf54), \uc720\ub7fd(\ub3c5\uc77c, \uc601\uad6d, \ud504\ub791\uc2a4, \uc774\ud0c8\ub9ac\uc544, \uc2a4\ud398\uc778 \ub4f1), \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591(\uc911\uad6d, \uc77c\ubcf8, \uc778\ub3c4, \ud638\uc8fc, \ud55c\uad6d \ub4f1), \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8 \ub4f1 \uc8fc\uc694 \uc9c0\uc5ed \ubc0f \uad6d\uac00\ubcc4 \uc2dc\uc7a5\uc744 \uc0c1\uc138\ud788 \ubd84\uc11d\ud569\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4\uc640 \uc8fc\uc694 \uae30\uc5c5\ub4e4\uc758 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \ub2e4\ub8e8\uba70, F. Hoffmann-La Roche Ltd, Merck &#038; Co., Inc., Bristol Myers Squibb Co., Amgen Inc., Novartis AG, Johnson &#038; Johnson, AstraZeneca, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, Regeneron Pharmaceuticals, AbbVie Inc., Seagen Inc., Daiichi Sankyo Co. Ltd, Sanofi SA, Genmab A\/S, BeiGene Ltd, Spectrum Pharmaceuticals Inc., Mitsubishi Tanabe Pharma, WuXi Biologics \ub4f1 20\uac1c \uc8fc\uc694 \uae30\uc5c5\uc758 \ud504\ub85c\ud544\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 WHO GLOBOCAN, CDC SEER, OECD Health Stats \ub4f1\uc758 \uacf5\uac1c \ub370\uc774\ud130\uc14b\uc744 \ud65c\uc6a9\ud55c \ub370\uc2a4\ud06c \ub9ac\uc11c\uce58\uc640 \uc885\uc591 \uc804\ubb38\uc758, \ubcd1\uc6d0 \uc57d\uc0ac, \uc9c0\ubd88\uc790, \uc9c0\uc5ed \uc720\ud1b5\uc5c5\uccb4\uc640\uc758 \uad6c\uc870\ud654\ub41c \uc778\ud130\ubdf0\ub97c \ud1b5\ud55c 1\ucc28 \uc870\uc0ac\ub97c \uacb0\ud569\ud55c \ud558\ud5a5\uc2dd \ubc0f \uc0c1\ud5a5\uc2dd \ubaa8\ub378\uc744 \uae30\ubc18\uc73c\ub85c \uc2dc\uc7a5\uc744 \ubd84\uc11d\ud558\uace0 \uc608\uce21\ud569\ub2c8\ub2e4. \ub370\uc774\ud130\ub294 \ub9e4\ub144 \uc5c5\ub370\uc774\ud2b8\ub418\uba70, \uc8fc\uc694 \uc2b9\uc778, \uac00\uaca9 \uc870\uc815, \uc0c1\ud658 \uc815\ucc45 \ubcc0\ud654 \uc2dc \uc911\uac04 \uc5c5\ub370\uc774\ud2b8\uac00 \uc774\ub8e8\uc5b4\uc9d1\ub2c8\ub2e4.<\/p>\n<p>\uacb0\ub860\uc801\uc73c\ub85c, \uc554 \ub2e8\uc77c\ud074\ub860\ud56d\uccb4 \uc2dc\uc7a5\uc740 \ub192\uc740 \uc131\uc7a5 \uc7a0\uc7ac\ub825\uc744 \uac00\uc9c0\uace0 \uc788\uc73c\uba70, \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\ubc95 \uac1c\ubc1c\uacfc AI \uae30\uc220\uc758 \uc811\ubaa9\uc744 \ud1b5\ud574 \ubbf8\ub798 \uc804\ub9dd\uc774 \ubc1d\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uaddc\uc81c \ubc0f \uc81c\uc870\uc0c1\uc758 \ub3c4\uc804 \uacfc\uc81c\ub4e4\uc744 \uadf9\ubcf5\ud558\ub294 \uac83\uc774 \uc911\uc694\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-35521","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/35521"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=35521"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/35521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=35521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=35521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=35521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}